Ocugen Stock News

"We are pleased to be able to move our clinical program for Covaxin forward, which we hope will bring us closer to offering an alternative Covid-19 vaccine," Ocugen CEO Shankar Musunuri said in a statement.

Ocugen is co-developing Bharat Biotech''s Covaxin vaccine for Covid in US and Canada

India News: HYDERABAD: Ocugen Inc, Bharat Biotech''s partner for US and Canada, said the US drug regulator, US Food & Drug Administration (USFDA), has lifted the c.

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness dise

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, February 25, 2022.

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseas

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re investing in OCGN stock, you have to wonder: how much upside can FDA approval really give this beleaguered name? The post Ocugen Stock Is a Fairy Tale in Need of a Happy Ending appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” Get in Now on Tiny $3 ‘Forever Battery’ Stock Interested in Crypto? Read This First…

If you're investing in OCGN stock, you have to wonder: how much upside can FDA approval really give this beleaguered name? The post Ocugen Stock Is a Fairy Tale in Need of a Happy Ending appeared firs

There are much better options than these two companies on the stock market.

A broad stock market rebound and an encouraging survey appear to be boosting these vaccine stocks.

A broad stock market rebound and an encouraging survey appear to be boosting these vaccine stocks.

A broad stock market rebound and an encouraging survey appear to be boosting these vaccine stocks.

Ocugen Inc. (NASDAQ:OCGN) price on Thursday, February 10, rose 2.53% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.08. A look at the stock’s price movement, the level at last check in today’s session was $3.98, moving within a range at $3.5124 and $3.986. The beta value … Ocugen Inc. (OCGN) Has A Potential Gold Mine Read More »

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry A ge-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight''s '' Dry Age-related Macular Degeneration Pipeline Insight 2021 '' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight''s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.